Ubuhlungu be-Post-Operative buncishisiwe ngokusetshenziswa kwe-CBD

Ithebhulethi emuncwa ngomlomo equkethe i-cannabidiol (CBD) inciphisa ngempumelelo ubuhlungu ngemva kokuhlinzwa kwehlombe ngaphandle kokukhathazeka ngokuphepha, ucwaningo olusha luthola.      

Iholwa abacwaningi eMnyangweni Wokuhlinza Amathambo e-NYU Langone Health, ucwaningo lwathola ukuthi ithebhulethi i-ORAVEXX ilawule ubuhlungu ngokuphepha ngemva kokuhlinzwa kwe-rotator cuff encane, futhi ayizange ikhiqize imiphumela emibi ngezinye izikhathi ehlotshaniswa nokusetshenziswa kwe-CBD, njengokucanuzela kwenhliziyo, ukukhathazeka, kanye ubuthi besibindi. Okutholakele kwethulwe eMhlanganweni Wonyaka we-American Academy of Orthopedic Surgeon's (AAOS) 2022 e-Chicago.

"Kunesidingo esiphuthumayo sezinye izindlela ezisebenzayo zokulawula ubuhlungu, futhi ucwaningo lwethu luveza lolu hlobo lwe-CBD njengethuluzi elithembisayo ngemuva kokulungiswa kwe-cuff ye-arthroscopic rotator," kusho umphenyi oholayo uMichael J. Alaia, MD, FAAOS, uprofesa ohlangene eMnyangweni we Ukuhlinzwa Kwamathambo. "Kungaba indlela entsha, engabizi kakhulu yokuletha ukukhululeka kobuhlungu, futhi ngaphandle kwemiphumela emibi yezidakamizwa ezilwa nokuvuvukala njengama-NSAID kanye nezingozi zokulutha ezixhunywe kuma-opiates. Ukwengeza, i-CBD inenzuzo yokukhulula ubuhlungu ngaphandle kwemiphumela ye-psychotropic ehlotshaniswa ne-THC noma insangu. "

Isivivinyo somtholampilo sesigaba 1/2 esigxile ezintweni eziningi sihlele abahlanganyeli abangu-99 ngokungahleliwe kuzo zonke izizinda zocwaningo ezingu-2 (i-NYU Langone Health ne-Baptist Health/Jacksonville Orthopedic Institute) abaneminyaka yobudala ephakathi kwe-18 ne-75 eqenjini le-placebo kanye neqembu elithola i-CBD emuncwa ngomlomo. Ababambiqhaza banqunyelwe umthamo ophansi we-Percocet, bayalwe ukuba bakhiphe i-narcotic ngokushesha ngangokunokwenzeka, futhi bathathe i-placebo/CBD izikhathi ezi-3 ngosuku izinsuku ezingu-14 ngemva kokuhlinzwa. 

Ngosuku lokuqala ngemva kokuhlinzwa, iziguli ezithola i-CBD zezwa ngokwesilinganiso ubuhlungu obuncane ngamaphesenti angu-23 njengoba kukalwa ngesilinganiso sobuhlungu be-analog scale (VAS) uma kuqhathaniswa neziguli ezithola i-placebo, okugqamisa ukuthi ezigulini ezinobuhlungu obumaphakathi, i-CBD ingase inikeze inzuzo enkulu. . Kuzo zombili izinsuku zokuqala nezesibili ngemuva kokuhlinzwa, iziguli ezithola i-CBD zibike ukwaneliseka okukhulu ngamaphesenti angama-22 kuye kwangama-25 ngokulawulwa kobuhlungu uma kuqhathaniswa nalezo ezithola i-placebo. Ukuhlaziywa okwengeziwe kuphinde kwabonisa ukuthi iziguli ezithola i-50 mg ye-CBD zibike ubuhlungu obuphansi kanye nokwaneliseka okuphezulu ngokulawulwa kobuhlungu uma kuqhathaniswa neziguli ezithola i-placebo. Ayikho imiphumela emibi emikhulu ebikiwe.

Nakuba imiphumela iyathembisa, uDkt. Alaia uxwayise abathengi ngokufuna imikhiqizo ye-CBD edayiswayo. “Ucwaningo lwethu luhlola umkhiqizo oklanywe kahle, ocutshungulwe ngokucophelela ngaphansi kwesicelo somuthi esisha esiphenywayo esigunyazwe yi-FDA. Lona okwamanje kusewumuthi ohlolwayo futhi awukakatholakali ukuze unikezwe ngudokotela,” uyanezela.

I-ORAVEXX, ithebulethi emuncwe ngobuningi esetshenziswa kulolu cwaningo, iklanywe futhi yakhiqizwa yi-Orcosa Inc., inkampani yesayensi yezempilo. Iwukwakheka kwe-CBD engaluthisi, emunca ngokushesha eyakhelwe ukwelapha izinhlungu.

Ukuqhubekela phambili, i-NYU Langone yethule ucwaningo lwesibili olubheka ukuthi i-ORAVEXX ingakwazi yini ukwelapha ubuhlungu obungapheli ezigulini ezine-osteoarthritis. Izifundo eziningi zesigaba sesi-2 nazo zihlelelwe ukuhlola ukusebenza komuthi kwezinye izinkinga zokulawula izinhlungu ezinzima nezingamahlalakhona kanye nokuhlola indima ye-CBD ekuvuvukeni.